ALRN
Price
$6.50
Change
-$0.59 (-8.32%)
Updated
Mar 28, 6:59 PM EST
GLYC
Price
$3.00
Change
-$0.18 (-5.66%)
Updated
Mar 28, 6:59 PM EST
34 days until earnings call
Ad is loading...

ALRN vs GLYC ᐉ Comparison: Which is Better to Invest?

Header iconALRN vs GLYC Comparison
Open Charts ALRN vs GLYCBanner chart's image
Aileron Therapeutics
Price$6.50
Change-$0.59 (-8.32%)
Volume$11.92K
CapitalizationN/A
GlycoMimetics
Price$3.00
Change-$0.18 (-5.66%)
Volume$392.55K
CapitalizationN/A
View a ticker or compare two or three
ALRN vs GLYC Comparison Chart

Loading...

ALRNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GLYCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ALRN vs. GLYC commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALRN is a StrongSell and GLYC is a StrongSell.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (ALRN: $6.63 vs. GLYC: $3.02)
Brand notoriety: ALRN and GLYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALRN: 70% vs. GLYC: 187%
Market capitalization -- ALRN: $32.39M vs. GLYC: $194.47M
ALRN [@Biotechnology] is valued at $32.39M. GLYC’s [@Biotechnology] market capitalization is $194.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALRN’s FA Score shows that 0 FA rating(s) are green whileGLYC’s FA Score has 0 green FA rating(s).

  • ALRN’s FA Score: 0 green, 5 red.
  • GLYC’s FA Score: 0 green, 5 red.
According to our system of comparison, ALRN is a better buy in the long-term than GLYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALRN’s TA Score shows that 4 TA indicator(s) are bullish while GLYC’s TA Score has 5 bullish TA indicator(s).

  • ALRN’s TA Score: 4 bullish, 4 bearish.
  • GLYC’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ALRN and GLYC are a good buy in the short-term.

Price Growth

ALRN (@Biotechnology) experienced а +16.93% price change this week, while GLYC (@Biotechnology) price change was +4.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

ALRN is expected to report earnings on May 08, 2023.

GLYC is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ALRN with price predictions.
OPEN
A.I.dvisor published
a Summary for GLYC with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
GLYC($194M) has a higher market cap than ALRN($32.4M). ALRN YTD gains are higher at: 117.477 vs. GLYC (27.966). ALRN has higher annual earnings (EBITDA): -12.64M vs. GLYC (-40.13M). GLYC has more cash in the bank: 49.4M vs. ALRN (12.1M). ALRN has less debt than GLYC: ALRN (0) vs GLYC (1.01M). ALRN (0) and GLYC (0) have equivalent revenues.
ALRNGLYCALRN / GLYC
Capitalization32.4M194M17%
EBITDA-12.64M-40.13M31%
Gain YTD117.47727.966420%
P/E Ratio0.14N/A-
Revenue00-
Total Cash12.1M49.4M24%
Total Debt01.01M-
FUNDAMENTALS RATINGS
ALRN vs GLYC: Fundamental Ratings
ALRN
GLYC
OUTLOOK RATING
1..100
8213
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3436
P/E GROWTH RATING
1..100
79100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALRN's Valuation (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for GLYC (86) in the Biotechnology industry. This means that ALRN’s stock grew somewhat faster than GLYC’s over the last 12 months.

ALRN's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GLYC (100) in the Biotechnology industry. This means that ALRN’s stock grew similarly to GLYC’s over the last 12 months.

ALRN's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as GLYC (98) in the Biotechnology industry. This means that ALRN’s stock grew similarly to GLYC’s over the last 12 months.

ALRN's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as GLYC (36) in the Biotechnology industry. This means that ALRN’s stock grew similarly to GLYC’s over the last 12 months.

ALRN's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as GLYC (100) in the Biotechnology industry. This means that ALRN’s stock grew similarly to GLYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALRNGLYC
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 18 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ALRNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GLYCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSLIX47.540.14
+0.30%
Hartford Small Cap Growth I
JSEZX42.56N/A
N/A
JPMorgan Small Cap Equity R2
TAISX10.90N/A
N/A
TIAA-CREF Quant Intl Sm-Cp Eq Advisor
NWAWX16.45N/A
N/A
Nationwide GQG US Quality Eq Instl Ser
RISSX11.09N/A
N/A
RBC International Small Cap Equity A

ALRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALRN has been loosely correlated with KZIA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ALRN jumps, then KZIA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALRN
1D Price
Change %
ALRN100%
-4.34%
KZIA - ALRN
35%
Loosely correlated
-1.24%
BIOR - ALRN
31%
Poorly correlated
-5.30%
CGTX - ALRN
29%
Poorly correlated
N/A
BCRX - ALRN
25%
Poorly correlated
-1.55%
AADI - ALRN
25%
Poorly correlated
-1.27%
More

GLYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been loosely correlated with IONS. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GLYC jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
-5.03%
IONS - GLYC
36%
Loosely correlated
-2.93%
AXON - GLYC
36%
Loosely correlated
-0.98%
MDGL - GLYC
34%
Loosely correlated
+3.18%
ALLO - GLYC
33%
Loosely correlated
N/A
AGIO - GLYC
33%
Loosely correlated
+0.27%
More